	Application No.	Applicant(s)
Notice of Allowability .	09/911,703	ANDERSON ET AL.
	Examiner	Art Unit
	Ron Schwadron, Ph.D.	1644
The MAILING DATE of this communication appearance All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
1. This communication is responsive to <u>AMENDMENT OF 3/</u>	<u>29/07</u> .	
2. The allowed claim(s) is/are <u>21,26,42,47,48,51-53,58,59 and</u>	<u>nd 70-72</u> .	
 Acknowledgment is made of a claim for foreign priority una)	e been received. e been received in Application No cuments have been received in this r of this communication to file a reply of	national stage application from the complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. 		
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal Pa	atent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary Paper No./Mail Date	ė
 3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material 		nent/Comment
II.S. Patent and Trademark Office	9.	Question of the control of the contr

Application/Control Number:

09/911,703 Art Unit: 1644

- 1. Regarding applicants comments in the response of 2/16/07, the amending of claim 21 in the amendment of 8/21/05 broadened the scope of the claim because it removed sequences encoding the signal peptide (aka the claim went from an antibody with signal sequences to an antibody without signal sequences). The antibody of Anderson et al. (1991) did not include the signal sequences present in the claim prior to amendment and thus did not constitute art until said signal sequences were removed from the claim.
- 2. In view of the papers filed 3/29/07, the inventorship in this nonprovisional application has been changed by the deletion of John E. Leonard.

The application will be forwarded to the Office of Initial Patent Examination (OIPE) for issuance of a corrected filing receipt, and correction of Office records to reflect the inventorship as corrected.

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. The rejection of Claims 21,26,29-32,41-43,45-48,51-58,60-62,68-72 under the judicially created doctrine of obviousness-type double patenting as being unpatentable

09/911,703 Art Unit: 1644

over claims 1-6 of U.S. Patent No. 5,736,137 is withdrawn in view of the TD filed 3/29/07 and the cancellation of claims that have been cancelled.

- 5. The following is a quotation of the first paragraph of 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 6. The rejection of claims 41,43,45-48,51-57,69 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement for the reasons elaborated in the previous Office action is withdrawn in view of the cancellation of claims that were cancelled and the amended claims.
- 7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- 8. The rejection of claims 41,43,45-48,51-57,69 under 35 U.S.C. 102(b) as being anticipated by Anderson et al. (US Patent 5,736,137) for the reasons elaborated in the previous Office Action is withdrawn in view of the cancellation of claims that have been cancelled and the amended claims.

Application/Control Number:

09/911,703 Art Unit: 1644

- 9. The rejection of claims 21,26,41,42,58,59,69,70 under 35 U.S.C. 102(a) as being anticipated by Anderson et al. (1991) is withdrawn in view of the Anderson declarations filed 3/29/07 and applicants arguments.
- 10. Claims 21,26,42,47,48,51-53,58,59,70-72 are allowed.
- 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ron Schwadron, Ph.D. whose telephone number is 571 272-0851. The examiner can normally be reached on Monday-Thursday 7:30-6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara can be reached on 571 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

COMMENT OF SECUMENT OF SECURE OF S

Ron Schwadron, Ph.D. Primary Examiner Art Unit 1644